Others

Applications Lindane-d6 is very toxic. It was an effective insecticide on mosquitoes, house flies, and on German and American cockroaches.
References Tanaka, K., et al.: Pestic. Biochem. Physiol., 6, 386-391 (1976)

Impurity Entacapone EP Impurity A
Applications cis-Entacapone (Entacapone EP Impurity A) is the (Z)-Isomer of Entacapone polymorphic form B. Antiparkinsonian.
References Karlsson, M., et al.: J. Pharm. Biomed. Anal., 10, 593 (1992), Nissinen, E., et al.: Arch. Pharmacol., 346, 262 (1992), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),

Applications Hexamethyldisilazane is used in the preparation of 5-azacytidine, an antineoplastic drug. Also used in the preparation of β3-AR agonists used in anti-stress formulations.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Vujjini, S. et al.: Org. Proc. Res. Dev., 17, 303 (2013); Xu, F. et al.: Org. Lett., 15, 1342 (2013);

Applications 3-Phenoxy-1,2-propanediol (cas# 538-43-2) is a useful research chemical.

Applications A metabolite of Furazolidone and Nitrofuran.Environmental contaminants; Food contaminants; Heat processing contaminants
References Mir, G., et al.: Indian J. Anim. Sci., 54, 888 (1984), Gottschall, D., et al.: J. Agric. Food Chem., 43, 2520 (1995)

Applications A labelled metabolite of Zopiclone.

Stability Moisture Sensitive
Applications 4-​Amino-​2-​fluoro-​N-​methylbenzamide acts as a reagent in the design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists. Also, in the preparation and structure-activity relationship of chiral benzyloxypyridinone derivatives as c-Met kinase inhibitors
References Ivachtchenko, A. V., et al.: Eur. J. Med. Chem., 99, 51 (2015); Zhang, D., et al.: Bioorg. Med. Chem. Lett., 23, 2408 (2013)

Applications 7-Ketoabiraterone Acetate is an impurity of Abiraterone (A108490), a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
References Denis, L., et al.: Cancer, 72, 3888 (1993); Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995); Denmeade, S., et al.: Nat. Rev., 2, 389(2002); Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005)